Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Core Viewpoint - Anavex Life Sciences Corp. is focused on developing innovative treatments for various CNS disorders, including Alzheimer's and Parkinson's diseases, and will present at the Citizens Life Sciences Conference on March 10, 2026 [1] Company Overview - Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [2] - The lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [2] - ANAVEX®2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its ability to halt or reverse Alzheimer's disease progression [2] - The company also has another candidate, ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, showing promise in addressing cognitive deficits and other Alzheimer's disease hallmarks in preclinical trials [2]